Dr. Bryan Dechairo is the chief executive officer of Sherlock Biosciences and also serves on the company’s Board of Directors. Bryan joins Sherlock with more than 20 years of experience developing and commercializing revenue generating clinical innovations that improve patient lives.
Prior to Sherlock, Bryan served as executive vice president of clinical development at Myriad Genetics, where he oversaw the development portfolio, delivering business-critical evidentiary data for value-based reimbursement and market acceptance of commercial and novel diagnostic products across six business units globally. Before joining Myriad, he was chief medical officer, chief scientific officer and senior vice president of research and development at Assurex Health, which was acquired by Myriad in 2016. During his extensive career, Bryan held roles of increasing responsibility at Medco, Pfizer, Oxagen, Sequana and Roche, where he established a proven track record of funding and scaling business from venture backed start-ups to profitable fortune 50 public companies.
Bryan has authored more than 50 academic and research-based publications, and earned a Ph.D. in Common Complex Human Genetics from the Institute of Child Health at University College London and a B.A. in Integrative Biology from the University of California, Berkeley.
Pardis Sabeti M.D., Ph.D., is a professor at the Center for Systems Biology and Department of Organismic and Evolutionary Biology at Harvard University and the Department of Immunology and Infectious Disease at the Harvard School of Public Health, an Institute Member of the Broad Institute of Harvard and MIT, and an investigator of the Howard Hughes Medical Institute.
Her computational genomic lab has contributed to widely varying fields — including human evolutionary biology, viral sequencing, information theory, rural disease surveillance, and education efforts in West Africa. The lab aims to create comprehensive approaches for detecting, containing, and treating deadly infectious diseases, including Lassa virus, Ebola virus, Zika virus, and Babesiosis microtia. Dr. Sabeti has invested in capacity building and education throughout the continent, enabling the first diagnoses of Ebola in Sierra Leone and Nigeria, training over 70 African scientists through summer-long educational programs, and establishing genome centers in West Africa.
Born in Tehran, Dr. Sabeti immigrated to the United States at the age of two. She completed her undergraduate degree in biology at MIT and her doctorate at Oxford University as a Rhodes Scholar. After that, she obtained her medical degree summa cum laude from Harvard Medical School as a Soros Fellow. Dr. Sabeti has received numerous awards and honors including World Economic Forum (WEF) Young Global Leader, National Geographic Emerging Explorer, Smithsonian American Ingenuity Award for Natural Science, TIME’s “Person of the Year” as one of the Ebola fighters, and TIME’s “100 Most Influential.”
She is also the host of “Against All Odds,” which is included as part of the AP Statistics curriculum nationwide, and is the lead singer of the rock band Thousand Days.
James Scavone is the vice president of finance and controller at Sherlock Biosciences. James brings more than 20 years of experience in finance and operations, focused on scaling the financial operations for emerging and established life sciences companies. Overseeing Sherlock’s finance and accounting operations, James provides critical financial analysis to support Sherlock’s strategic goals, while also providing results-driven leadership to build company infrastructure and systems to support growth across all departments.
James joins Sherlock from bluebird bio, where he led financial operations and oversaw system setups and integrations. Prior to bluebird bio, Jim served in accounting roles of increasing responsibility at Merrimack Pharmaceuticals, where he ascended to the position of manufacturing controller, overseeing production system setups and ongoing operations for the launch of commercially approved products.
James holds a Bachelor of Sciences in Business Administration with a concentration in accounting from University of New Hampshire Peter T. Paul College of Business and Economics.
Contact us to learn more about The 221b Foundation.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.